← Back
Caravaggio Room
December, 02nd | 10:30 - 11:15
HIGHLIGHTED FREE PAPERS INNOVATIVE THERAPIES
Add to calendar
Chairs: TADAYONI RAMIN, REGILLO CARL D., HOLZ FRANK
December, 02nd | 10:30 - 10:34
Outer retinal and choroidal changes in adolescents with long-lasting type 1 diabetes
PILOTTO ELISABETTA
Add to calendar
Outer retinal and choroidal changes in adolescents with long-lasting type 1 diabetes
PILOTTO ELISABETTA
Add to calendar
December, 02nd | 10:34 - 10:38
Intravitreal anx007, a selective classical complement inhibitor, as treatment for geographic atrophy secondary to age-related macular degeneration and impact on visual function measures: results of the archer study
MONES JORDI
Add to calendar
Intravitreal anx007, a selective classical complement inhibitor, as treatment for geographic atrophy secondary to age-related macular degeneration and impact on visual function measures: results of the archer study
MONES JORDI
Add to calendar
December, 02nd | 10:38 - 10:42
Photodynamic therapy for neovascular age-related macular degeneration in the era of injectables: meta-analysis of published studies and clinical trials
HADZIAHMETOVIC MAJDA
Add to calendar
Photodynamic therapy for neovascular age-related macular degeneration in the era of injectables: meta-analysis of published studies and clinical trials
HADZIAHMETOVIC MAJDA
Add to calendar
December, 02nd | 10:42 - 10:46
Investigating multimodal imaging to guide disease activity assessment in brolucizumab-treated patients with wet age-related macular degeneration: ad-interim results of imagine clinical study
STAURENGHI GIOVANNI
Add to calendar
Investigating multimodal imaging to guide disease activity assessment in brolucizumab-treated patients with wet age-related macular degeneration: ad-interim results of imagine clinical study
STAURENGHI GIOVANNI
Add to calendar
December, 02nd | 10:46 - 10:50
Efficacy and safety of ct-p42 compared to reference aflibercept (afl) in diabetic macular edema (DME): 24-week results from the phase 3 ct-p42 3.1 study.
STANGA PAULO
Add to calendar
Efficacy and safety of ct-p42 compared to reference aflibercept (afl) in diabetic macular edema (DME): 24-week results from the phase 3 ct-p42 3.1 study.
STANGA PAULO
Add to calendar
December, 02nd | 10:50 - 10:54
A novel device for simple, targeted drug delivery to the retina
BARAK ADIEL
Add to calendar
A novel device for simple, targeted drug delivery to the retina
BARAK ADIEL
Add to calendar
December, 02nd | 10:54 - 10:58
Efficacy and safety of mco-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: 12-month results from a phase 2b, randomized, sham-controlled, multi-center, multi-dose, patient- and assessor-masked clinical trial (restore)
BANDELLO FRANCESCO
Add to calendar
Efficacy and safety of mco-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: 12-month results from a phase 2b, randomized, sham-controlled, multi-center, multi-dose, patient- and assessor-masked clinical trial (restore)
BANDELLO FRANCESCO
Add to calendar
December, 02nd | 10:58 - 11:02
Intravitreal pegcetcaplan in geographic atrophy (GA): therapeutic effects on retinal pigment epithelium (RPE) and photoreceptor (pr) degeneration and function in the phase 3 clinical trials
REITER GREGOR
Add to calendar
Intravitreal pegcetcaplan in geographic atrophy (GA): therapeutic effects on retinal pigment epithelium (RPE) and photoreceptor (pr) degeneration and function in the phase 3 clinical trials
REITER GREGOR
Add to calendar
December, 02nd | 11:02 - 11:06
Safety and efficacy of intravitreal injection of Cord Blood and Platelet-Rich-Plasma (CB-PRP) in dry age-related macular degeneration (AMD)
SAVASTANO MARIA CRISTINA
Add to calendar
Safety and efficacy of intravitreal injection of Cord Blood and Platelet-Rich-Plasma (CB-PRP) in dry age-related macular degeneration (AMD)
SAVASTANO MARIA CRISTINA
Add to calendar
December, 02nd | 11:06 - 11:10
Update on Sozinibercept. A new “trap” inhibitor of VEGF C and D under development for the treatment of nAMD
MINNELLA ANGELO MARIA
Add to calendar
Update on Sozinibercept. A new “trap” inhibitor of VEGF C and D under development for the treatment of nAMD
MINNELLA ANGELO MARIA
Add to calendar
